查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138159

急性骨髓性白血病（AML）：市場展望、流行病學、競爭格局、市場預測報告（2026-2036年）

Acute Myeloid Leukemia (AML) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國反洗錢市場預計將從 2026 年的 3.05 億美元成長到 2036 年的 6.9 億美元。
  • 以下因素正在推動市場成長：
  • 擴大標靶治療和新型聯合治療的應用
  • 持續研發下一代急性骨髓性白血病（AML）療法
  • 未來的成長取決於能否開發出克服治療抗藥性並帶來持續臨床療效的療法。

急性骨髓性白血病市場展望及預測

急性骨髓性白血病概述

急性骨髓性白血病(AML) 是一種高度侵襲性的骨髓惡性腫瘤，其特徵是異常髓系前驅細胞的克隆性增殖，從而抑制血細胞的生成。患者可能出現血球減少、感染疾病和出血，預後取決於年齡、身體狀況、分子特徵和可測量的殘留病灶。治療方案包括強化誘導化療，以及使用Azacitidine或地西Decitabine濱合併維奈托克的方案，合格的患者可進行強化治療或異體造血幹細胞移植。標靶治療包括標靶 FLT3、IDH1/2 和 menin 的藥物。 Levmenib 和 diftomenib 已獲 FDA 核准用於治療復發/難治性 NPM1 突變型 AML，Levmenib 也獲準用於治療伴隨 KMT2A 易位的急性白血病。 2026年，口服Decitabine/塞達祖利定聯合治療獲準用於無法接受強化誘導治療的新診斷患者。其主要目標包括降低殘留病灶、抗藥性、預防復發以及在低毒性下達到持續緩解。

主要亮點

  • 在西班牙，預計 AML 新病例數將基本保持平穩，從 2026 年的 2,380 例降至 2036 年的 2,368 例。
  • 急性骨髓性白血病（AML）是一種高度侵襲性的骨髓惡性腫瘤，其特徵是疾病進展迅速且死亡風險高。
  • 儘管標靶治療治療和聯合治療取得了進展，但復發和治療抗藥性仍然是重大挑戰。
  • 目前仍有大量未滿足的治療需求，亟需提高持續緩解率和長期存活率。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Syndax Pharmaceuticals
  • Ipsen
  • Hikma Pharmaceuticals LLC
  • Moleculin Biotech, Inc.
  • Janssen Research &Development, LLC
  • Hutchmed
  • AbbVie
  • Bristol-Myers Squibb
  • Akeso
  • Novartis Pharmaceuticals
  • PrECOG, LLC.
  • Allotera Therapeutics
  • Taiho Oncology, Inc.
  • OncoVerity, Inc.
  • PedAL BCU, LLC
  • Daiichi Sankyo Co., Ltd.
  • Actinium Pharmaceuticals
  • Celgene
  • AstraZeneca
  • Boehringer Ingelheim
  • Astellas Pharma Inc.
  • Amphista Therapeutics Ltd
  • Pfizer
  • Kyowa Kirin Co., Ltd.
  • Oryzon Genomics SA
  • Aptevo Therapeutics
  • Charm Therapeutics
  • Takeda
  • Cullinan Therapeutics Inc.
  • Kura Oncology, Inc.
  • GluBio Therapeutics Inc.
  • Solu Therapeutics, Inc.
  • Crossbow Therapeutics, Inc.
  • Remix Therapeutics
  • Aprea Therapeutics
  • Auron Therapeutics, Inc.
  • BeOne Medicines
  • NovaOnco Therapeutics Co., Ltd.
  • Rigel Pharmaceuticals
  • Aptose Biosciences Inc.
  • Eli Lilly and Company
  • Aspera Biomedicines, Inc.

目錄

第1章：主要調查結果和分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 一群已確診並正在接受藥物治療的人。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要治療方法－概述及關鍵意見領袖觀點
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Acute Myeloid Leukemia Market Outlook and Forecast

Thelansis's "Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Myeloid Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by clonal expansion of abnormal myeloid precursors that disrupt blood-cell production. Patients may develop cytopenias, infection, and bleeding, with prognosis shaped by age, fitness, molecular features, and measurable residual disease. Treatment ranges from intensive induction chemotherapy to regimens such as azacitidine or decitabine with venetoclax, followed by consolidation or allogeneic stem-cell transplantation in selected patients. Targeted therapy includes FLT3, IDH1/2, and menin-directed agents. Revumenib and ziftomenib are FDA-approved for relapsed/refractory NPM1-mutated AML, while revumenib is approved for KMT2A-translocated acute leukemia. In 2026 oral decitabine/cedazuridine plus venetoclax was approved for newly diagnosed patients unable to receive intensive induction. Priorities include measurable residual disease, resistance, relapse prevention, and durable remission with lower toxicity.

Key Highlights

  • In Spain, AML incidence cases are projected to remain broadly stable, from 2,380 in 2026 to 2,368 by 2036.
  • AML is an aggressive hematologic malignancy characterized by rapid disease progression and substantial mortality risk.
  • Despite advances in targeted therapies and combination regimens, relapse and treatment resistance remain major challenges.
  • Significant unmet need remains for therapies that improve durable remission and long-term survival.

Market Overview

  • The Germany AML market is projected to grow from $305M in 2026 to $690M by 2036.
  • Market growth is driven by:
  • Increasing adoption of targeted therapies and novel combination regimens
  • Continued development of next-generation AML treatments
  • Future growth will depend on therapies that overcome treatment resistance and deliver durable clinical responses.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2026-2036)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Syndax Pharmaceuticals
  • Ipsen
  • Hikma Pharmaceuticals LLC
  • Moleculin Biotech, Inc.
  • Janssen Research & Development, LLC
  • Hutchmed
  • AbbVie
  • Bristol-Myers Squibb
  • Akeso
  • Novartis Pharmaceuticals
  • PrECOG, LLC.
  • Allotera Therapeutics
  • Taiho Oncology, Inc.
  • OncoVerity, Inc.
  • PedAL BCU, LLC
  • Daiichi Sankyo Co., Ltd.
  • Actinium Pharmaceuticals
  • Celgene
  • AstraZeneca
  • Boehringer Ingelheim
  • Astellas Pharma Inc.
  • Amphista Therapeutics Ltd
  • Pfizer
  • Kyowa Kirin Co., Ltd.
  • Oryzon Genomics S.A.
  • Aptevo Therapeutics
  • Charm Therapeutics
  • Takeda
  • Cullinan Therapeutics Inc.
  • Kura Oncology, Inc.
  • GluBio Therapeutics Inc.
  • Solu Therapeutics, Inc.
  • Crossbow Therapeutics, Inc.
  • Remix Therapeutics
  • Aprea Therapeutics
  • Auron Therapeutics, Inc.
  • BeOne Medicines
  • NovaOnco Therapeutics Co., Ltd.
  • Rigel Pharmaceuticals
  • Aptose Biosciences Inc.
  • Eli Lilly and Company
  • Aspera Biomedicines, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)